TheStreet upgraded the shares of AGN in report on Wednesday, July 29 to "Buy" rating. They now have a $180.97 target price on the stock.
A number of other equities research analysts have also weighed in on the stock. Finally, Piper Jaffray Companies set a $227.00 price objective on Allergan and gave the stock a "hold" rating in a research note on Friday, October 6th. Citigroup decreased their price objective on Allergan from $280.00 to $240.00 and set a buy rating for the company in a report on Thursday, October 19th.
Analysts have given a mean recommendation of 2.20 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Allergan now has an average rating of "Hold" and an average price target of $226.95.
In recent trading action Allergan plc (NYSE:AGN) stock moved -0.88% landing at $176.05. The stock was trading at a distance of -31.03% from its 52-week highs and stands 10.65% away from its 52-week lows. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40.
Snowboarder Prior drops in to Winter Olympics contention
America closed out the rest of the podium with Chloe Kim on 88.75 points and Maddie Mastro third on 87.25. White took the gold at the 2006 Games in Turin, Italy, and again in Vancouver in 2014.
The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $59.07B.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $3.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.65 by $0.33. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the previous year, the firm posted $3.32 EPS. During the same quarter past year, the business posted $3.32 EPS.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 15th. Moreover, Green Square Capital Llc has 0% invested in the company for 11,120 shares. The rating was maintained by RBC Capital Markets on Thursday, August 3 with "Buy". This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.59%. Allergan's dividend payout ratio is presently -12.39%.
Allergan announced that its board has approved a stock buyback plan on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board believes its shares are undervalued.
Colisão entre veículos deixa dois mortos e seis feridos em Atalaia
Além das duas mortes, quatro pessoas tiveram lesões graves e duas, ferimentos leves. O quarto paciente está na ortopedia e também tem quadro clínico estável.
In related news, Director Christopher J. Coughlin bought 10,000 shares of the company's stock in a transaction that occurred on Tuesday, December 5th. The shares were purchased at an average price of $163.30 per share, with a total value of $1,633,000.00. The stock exchanged hands with 2,008,640 numbers of shares compared to its average daily volume of 3.76M shares. Insiders have purchased a total of 17,630 shares of company stock valued at $2,890,057 over the last three months. Mitchell Mcleod Pugh And Williams invested in 3,975 shares or 0.6% of the stock. It turned negative, as 3 investors sold Allergan plc shares while 3 reduced holdings. Cable Hill Partners LLC raised its position in Allergan by 255.2% in the 3rd quarter. Rockefeller Financial Services Inc. lifted its position in shares of Allergan by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company's stock valued at $111,000 after acquiring an additional 400 shares during the period. LLC lifted its stake in shares of Allergan by 334.8% in the second quarter. LLC now owns 500 shares of the company's stock worth $122,000 after purchasing an additional 385 shares during the period. Finally, Pacific Center for Financial Services lifted its position in shares of Allergan by 1.3% during the 2nd quarter. The firm owned 83,569 shares of the company's stock after selling 7,724 shares during the quarter.
COPYRIGHT VIOLATION WARNING: "Allergan (AGN) Downgraded by Vetr" was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States and global trademark and copyright laws. The original version of this article can be read at https://www.truebluetribune.com/2018/01/14/allergan-plc-agn-position-lowered-by-nisa-investment-advisors-llc.html.
Among 26 analysts covering Allergan Inc. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products.
Manifestantes depredam loja na África do Sul que fez publicidade racista
Em um dos casos, policiais tiveram que disparar balas de borracha para dispersar os manifestantes, acrescentou a polícia. A loja também disse que removeu a peça do mercado.